Navigation Links
Takeda Announces New U.S. Leadership
Date:3/19/2008

Proposed appointments effective at conclusion of TAP transaction

DEERFIELD, Ill., March 19 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced proposed new leadership for Takeda America Holdings, Inc. (TAH), Takeda Pharmaceuticals North America, Inc. (TPNA) and Takeda Global Research & Development Center, Inc. (TGRD) following an earlier announcement related to Takeda's plans to conclude its joint venture in the United States, TAP Pharmaceutical Products Inc. (TAP).

Effective at the close of the TAP transaction, Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. will report to Takeda America Holdings, Inc. Alan MacKenzie, the current president of TAP and a former president of Takeda Pharmaceuticals North America, Inc. has been named executive vice president of Takeda America Holdings.

MacKenzie will also serve as CEO of Takeda Pharmaceuticals North America, Inc. in addition to his role as executive vice president of Takeda America Holdings.

Mark Booth, current president of Takeda Pharmaceuticals North America, Inc., will continue to lead the company until the TAP transaction is closed and has agreed to continue on with the company for some period thereafter to support integration activities.

Reporting to MacKenzie as president of Takeda Global Research & Development Center, Inc. will be Nancy Joseph-Ridge, M.D., currently TAP's vice president of research and development. Dr. Joseph-Ridge will also assume her position effective the close of the TAP transaction.

"I have great confidence in Takeda's proposed new leadership for the United States, an important market for Takeda's global growth plans," said Yasuchika Hasegawa, president, Takeda Pharmaceutical Company Limited. "Alan MacKenzie not only helped launch both TPNA and its first product, Actos, he has been instrumental in helping create success at Takeda companies for more than 22 years. Dr. Nancy Joseph-Ridge is a well-known and highly respected physician, researcher and strong leader with an unwavering commitment to scientific excellence. I would also like to take this opportunity to thank Mark Booth for his many contributions to Takeda and wish him well in his future endeavors."

MacKenzie first joined TAP as a sales representative in 1985 and served in various senior-level roles for TAP, including vice president of sales and director of marketing. He holds a B.S.N. from Wagner College, a B.A. in economics from City University of New York, and a M.B.A. from the University of Chicago.

Prior to joining TAP in 2002, Dr. Joseph-Ridge worked for Searle, which later became part of Pfizer, in drug safety and clinical development. She previously held clinical and academic roles in Chicago at Rush-Presbyterian-St. Luke's Medical Center and the University of Chicago Hospitals. She received her M.D. from the University of Illinois at Chicago.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets products for diabetes, insomnia, wakefulness and gastroenterology. Through the Takeda Global Research & Development Center, Inc. the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Takeda submits new drug application for alogliptin (syr-322) in the US
2. Chemizon Announces Research Collaboration Expansion With Takeda
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
5. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
6. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
7. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
8. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
9. PRA International Announces New Office Opening in Mumbai
10. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
11. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology: